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Measuring Decision-Making Capacity in Cognitively Impaired Individuals
Abstract
Cognitive and functional losses are only part of the spectrum of disability experienced by persons with
Alzheimer's disease and related dementias. They also experience losses in the ability to make decisions,
known as decision-making capacity. Researchers have made substantial progress in developing a model
of capacity assessment that rests upon the concept of the 4 decision-making abilities: understanding,
appreciation, choice and reasoning. Empirical research has increased our understanding of the effects of
late-life cognitive impairment on a person's ability to make decisions. This review examines studies of the
capacity to consent to treatment, research and the management of everyday functional abilities. The
results illustrate the clinical phenotype of the patient who retains the capacity to consent. They also
suggest that measures of capacity can improve how researchers measure the benefits of cognitive
enhancements and stage dementia.
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Cognitive and functional losses are only part of the spectrum of disability experienced by persons
with Alzheimer's disease and related dementi as. They also experience losses in the ability to make
decisions, known as decision-making capacity. Researchers have made substantial progress in
developing a model of capacity assessment that rests upon the concept of the 4 decision-making
abilities: understanding, appreciation, choice and reasoning. Empirical research has increased our
understanding of the effects of late-life cogniti ve impairment on a person's ability to make decisions.
This review examines studies of the capacity to consent to treatment, research and the management
of everyday functional abilities. The results illustrate the clinical phenotype of the patient who retains
the capacity to consent. They also suggest that measures of capacity can improve how researchers
measure the benefits of cognitive enhancements and stage dementia.
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Why Should We Care about Decision-Making

Capacity in

Impaired Individuals?
The prevalence of cognitive impairment steadily increases with age [I]. In the United States
and other Western nations, the chief cause of this impairment is Alzheimer's disease and related
late-life neurodegenerative dementias. Persons with dementia are, by definition, disabled. That
is, the diagnosis requires evidence of a decline in a person's ability to perform his or her usual
and everyday tasks [2].
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Researchers have made considerable progress in measuring the pattern and progression of these
disabilities. Specifically, substantial data describe the kinds of functional losses persons with
dementia experience [3]. The earliest changes are in complex instrumental activities of daily
living, especially managing money, medications, telephone messages and transportation. By
the moderate to severe stages, knowledgeable informants report that the patient has difficulties
in performing basic activities of daily living (ADL).l

© 2008 S. Karger AG. Basel
Jason Karlawish. MD. University of Pennsylvania. Institute on Aging. 3615 Chestnut Street. Philadelphia. PA 19104 (USA). Tel. +1215
8988997. Fax +12156627812.
E-Mail Jason.karlawish@uphs.upenn.edu
1The basic ADL are u·ansferring. washing and grooming. dressing. feeding. and tOileting.
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Progress in this research has allowed the development of staging instruments such as the
Clinical Dementia Rating [4] and the ADCS-ADL inventory [5]. These instruments are also
valuable in assessing the effecti veness of potential treatments. For example. European
regulatory officials require that approval of an antidementia compound must show efficacy on
a functional measure in addition to measures of cognition and global change.
However. cogniti ve and functional losses are only part of the spectrum of disability experienced
by persons with Alzheimer's disease and related dementias. They also experience losses in
their ability to make decisions, also known as decision-making capacity. Unlike the field of
functional assessment that began in the 1960s when Powell Lawton and Elaine Brody published
their landmark article' Assessment of older people: self-maintaining and instrumental activities
of daily living' [6] , the science of capacity assessment is comparatively recent. The conceptual
and empirical framework was established in the 19S0s with the work of the MacArthur network
[7,S] and Marson and colleagues' studies of the capacity of persons with Alzheimer's disease
to consent to treatment [9].
The last 20 years have seen considerable progress in the science of capacity assessment. The
material reported in this paper is the result of several years of both conceptual and empirical
scholarship with collaborators at as well as outside the University of Pennsylvania. This work
has at least 3 benefits.
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First, it expands our understanding of the nature and severity of the kinds of disabilities persons
with cognitive impairment experience. Second, it introduces an additional method to assess
the clinical benefits of treatments for persons with cognitive impairment. For example,
measures of capacity can serve as endpoints to measure the effectiveness of a therapy to
enhance cognition. Finally, it provides conceptual and methodological coherence to resolving
ethically challenging decisions, such as whether a person with cognitive impairment retains
the ability to choose a risky treatment or enroll in a potentially burdensome clinical trial.
Capacity assessments negotiate the boundary between eitherrespecting a person's autonomous
choices or acting out of the principle of beneficence to promote that person's welfare.
Specifically, persons who lack capacity need someone else to decide for them.
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The Conceptual

Framework

of Capacity Assessment

A capacity assessment is a clinical assessment. The term clinical assessment captures 2
features. A health care practitioner talks to a patient to gather data, and then the professional
uses that data together with other relevant information to make a judgment whether the patient
does or does not have a diagnosis or has responded to an intervention.
An example of a clinical assessment is the use of a mood measurement scale to inform a
diagnosis of depression. Scores on the geriatric depression scale do not determine that a person
has depression. Instead, they are part of a clinical interview that informs the clinician's
judgment whether the patient has depression. For example, a person who scores 6 on the 15item geriatric depression scale [10], a score above the cutoff of 5, may in fact not be depressed
because, for example, his or her symptoms are the result of an acute grief reaction.
What does this have to do with capacity assessment? The data derived from a capacity
interview, like any clinical interview. inform the clinical judgment that the person lacks
sufficient capacity to make a decision on his or her own [11]. In such a case, someone else,
such as a close friend or family member, has to decide for the person. This judgment
incorporates the results of capacity assessment with the risks, benefits and immediacy of the
decision. For example, a clinician would be inclined to set a low threshold for judging a patient
capable of making a decision if the decision involves little risk and great benefit and must be
made relatively quickly.
NeuTosignais. Author manuscript; available in PMC 2009 July 29.
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The term capacity is distinct from the term competency [12]. Competency describes a legal
judgment. That is, only a judge can declare a person noncompetent. In contrast, a physician
judges whether someone has sufficient capacity to make a decision. The distinction made here
is based solely on who is making the judgment and the role society assigns that person.
Specifically, while judges do have the unique authority to declare a person not competent in a
legal context, meaning the person needs some form of a guardian to make decisions for him
or her, physicians make the same kind of decision all the time. On a day-to-day basis, clinicians
decide that a patient is not competent to decide whether to take a treatment and, therefore,
based on this assessment, the clinicians turn to a surrogate to choose on behalf of the patient.
In sum, the terms competency and capacity distinguish between legal and medical judgments,
but their outcomes are the same: a person can no longer choose for himself. In this paper, I will
use the term capacity in order to retain the dimension quality of the construct.

How to Measure Capacity
Capacity is a dimensional quality of a person. By dimensional, I mean it is akin to weight, body
mass index or blood pressure. A person's capacity is a point along a continuum. This continuum
is described by the 4 decision-making abilities.
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Considerable legal and ethical research has been undertaken in defining these abilities and
standards to measure them [13]. They are: understanding, appreciation, choice and reasoning.
Understanding is the ability to comprehend the meaning of information, such as the details of
a research protocol, its alternatives, and the benefits and harms of the options. Appreciation is
the ability to recognize how information applies to a person, information such as a diagnosis
and the risks and benefits of the range of possible solutions for that diagnosis. Reasoning is
the ability to compare options and infer the consequences of choices in a logically consistent
manner. Expressing a choice is the ability to state a decision.
The general strategy to measure decision-making ability is to ask a patient a series of questions
that assess that ability and to score those answers using criteria (for example: adequate answer
= 2, marginal answer = 1, inadequate answer = 0). The sum of scores for the questions then
represents a score on the measure of ability.
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For example, suppose a clinician wants to assess a mild-stage Alzheimer's disease patient's
capacity to consent to a treatment for Alzheimer's disease that carries a risk of encephalitis. In
measuring the patient's ability to understand this risk, the clinician would ask the person to
paraphrase the meaning of the information disclosed. Specifically, after the clinician discloses
this risk to the patient, he or she would ask the patient 'Tell me in your own words what I said
about the risk of the drug?' An answer such as 'It might damage my brain by causing it to get
inflamed' is an example of adequately understanding of the risk of encephalitis. If the clinician
was scoring performance, because for example, he or she was studying the capacity of patients
to make a decision, such an answer would receive a score of 2.
The clinician uses this same strategy to assess the abilities to appreciate, choose and reason.
In the case of assessing appreciation, the clinician needs to measure how well the person accepts
that facts, such as the benefits and risks of a treatment, apply to his or her particular situation .
For example, to demonstrate appreciation of the benefits of a treatment the patient needs to
express some plausible explanation why the treatment will or will not benefit him or her. In
particular, a patient with Alzheimer's disease who appreciates the benefits of a treatment might
state that she has some memory problems that she does not want to get worse and a drug that
can prevent that would be of value to her.
To assess the ability to reason, a clinician has 3 categories of questions: measuring a patient's
ability to compare 2 options, such as taking versus not taking a medication; measuring a
NeuTosignais.
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patient's ability to infer how a choice will affect his or her daily life; assessing the logical
consistency of the patient's answer to these 2 questions.
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At the close of a decision-making ability assessment, the clinician has a set of data that describes
the patient's performance on the 4 abilities, that is, how well the person can make the decision.
These data are the foundation for a judgment of whether the person has adequate capacity to
make a decision.

Studies of Capacity in Persons with Cognitive Impairment
In this section, I review ou r laboratory's work on studies of capacity in persons with cognitive
impairment. Much of this work has focused on the most common cause of cognitive
impairment, Alzheimer's disease. Before reviewing these results, I will overview the general
design of our research.
A capacity study, like any study to test a measure, relies on the principles ofreliability and
validity developed in psychology [14]. Reliability is assessed by examining internal
consistency, and inter- and intrascorer variability. Validity is assessed using the techniques of
convergent, divergent and criterion validity.
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Convergent and divergent validity refers to the association between 2 measures that either
measure similar (convergent) or different (divergent) things. For example, we would expect
that a valid measure of depression would show a positi ve association with a measure of anxiety,
because anxious people tend to be depressed, and, in contrast, the measure of depression should
show a negative association with a measure of happiness, because depressed people tend not
to be happy. Criterion validity refers to the degree that summary scores of a measure differ
between 2 groups who are expected to differ with respect to the measure under study. Thus,
persons with diagnosed major depression should have higher scores on the depression scale
than persons who are not diagnosed as having major depression.
In studies of capacity assessment, typical measures for convergent and divergent validity
include measures of cognition, both overall cognition and specific domains of cognition such
as executive function, and other measures of capacity. Two common criterion measures are
comparing patient performance to a group who is expected to perform well on the measures
of ability, such as cognitively normal elderly or knowledgeable informants, and expert
judgments of whether the person has sufficient capacity to make the decision on his or her own.
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The studies summarized below cover a spectrum of decisions: treatment for Alzheimer's
disease, consent to research, and solving everyday functional problems. It should be evident
that there are as many ways to measure capacity as there are unique decisions. For example,
researchers have developed instruments to assess the capacity to stand trial [15] and to vote
[16].

The Capacity to Consent to Treatment
Previous research on Alzheimer's disease patients' capacity to consent to treatment has focused
on decisions about hypothetical health states (cardiac disease or a brain tumor) [9]. We were
interested in examining the more clinically relevant issue, namely patients' capacity to decide
about treatment for their Alzheimer's disease. Our study addressed 3 questions [17]:
1. What is the clinical significance of patients' impairments in decision-making
abilities?
2.

How is the loss of insight related to the other decision-making abilities and
determinations of competency?

Neurosigna!s. Author manuscdpt; available in PMC 2009 July 29.
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What is the relationship between overall cognition and judgments of competency?

The value of these questions rests upon 3 interrelated issues. Treatments for Alzheimer's
disease may carry substantial risks [18]. Therefore, clinicians and family members could
benefit from knowing the characteristics of patients who are capable of deciding whether to
take a risky treatment. Two characteristics warrant study: insight and the severity of a patient's
cognitive impairments.
Persons with Alzheimer's disease often have diminished insight into their cognitive and
functional deficits [19] , but it is not known how these impairments relate to their performance
on measures of capacity. We were especially interested in learning how patients' failure to
endorse the presence of cognitive impairments, their prognosis and the diagnosis of
Alzheimer's disease impacts on their ability to decide whether to receive a risky treatment.
These data can assist clinicians' and families' understanding of why a patient cannot make a
decision. Moreover, if deficits in insight are in fact associated with the lack of capacity,
clinicians and families have reason to take steps to foster a patient's insight, such as diagnostic
disclosure and participation in a support group for persons with cognitive impairment.
It is also important to examine the association between capacity and the severity of cognitive
impairments because diagnostic criteria are moving to diagnosing Alzheimer's disease in
persons with mild degrees of cognitive impairment [20,21]. In particular, it is important to
understand differences across the stages defined by traditional cut points on the mini-mental
state examination (MMSE) [22].
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Why use the MMSE? The answer to this question rests upon the clinical value of this measure
of overall cognition. The MMSE is one of the few measures of overall cognition that is widely
used in dementia clinical practice and to set eligibility criteria for clinical trials to test new
treatments. Showing associations between both capacity and traditional MMSE cut points gives
clinicians additional tools to better understand how the stages of dementia affect their patient's
ability to make a decision.
Measuring the Capacity to Consent to Treatment-We used the MacArthur Capacity
Assessment Tool for Treatment (MacCAT-T) [23] to assess the 4 decision-making abilities in
2 groups: persons with very mild to moderate Alzheimer's disease (n = 48) and their family
caregivers (n = 102). We then asked 3 expert psychiatrists to independently listen to the patient
interviews and judge whether the patient was competent to consent to the treatment. The
Alzheimer's disease treatment was modeled after a disease-slowing therapy with a risk of
gastrointestinal bleeding using a scenario we have developed and tested in previous research
investigating caregivers' tolerance for risk to treat Alzheimer's disease [24].
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The Capacity to Consent to Treatment in Persons with Alzheimer's DiseaseAmong the 48 patients with mild to moderate Alzheimer's disease, we found considerable
variation in patients' performance on the measures of 4 decision-making abilities. In contrast,
the comparison group of 102 family caregivers generally performed quite well on the 4
measures. Results on the measure of appreciation were especially interesting. We found
marked differences in the abilities of the patients to appreciate the risk versus the benefit of
the medicine. Specifically, only 7/48 (15%) could fully appreciate the benefit, while 19/48
(40%) could fully appreciate the risk. Three expert raters found 19/48 (40%) of the subjects
had the capacity to provide their own informed consent.
Relationships between Capacity to Consent and Insight-Patients
judged capable
of consent were more likely to show awareness of their symptoms, prognosis and diagnosis.
Of particular importance, this association between insight and being judged competent to

Neurosignais. Author manuscript; available in PMC 2009 July 29.
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consent to treatment was independent of the patients' overall cognitive function. In other words,
the impact of impairments in insight was independent of the impact of the severity of overall
cognition. After adjusting for MMSE performance, patients who had insight into their memory
problems (OR = 4.5, p = 0.04, 95% CI 1.1-17.9) and diagnosis of Alzheimer's disease (OR =
4.1, p = 0.04,95% CI 1.0-16.4) were more likely than patients who did not have these insights
to be judged to have the capacity to provide consent. Among patients with insight into their
prognosis, there was a trend suggesting that independent of overall cognitive function,
awareness of prognosis is associated with being judged to have the capacity to provide consent
(OR = 3.4, p = 0.08, 95% CI 0.85- 13.7).
Relationships between Competency to Consent and Overall Cognition-We
examined the sensitivity and specificity of being judged not competent to consent as a function
of performance on the MMSE. MMSE scores below 19 showed increasing specificity, meaning
competent patients are not likely to be mistakenly labeled as noncompetent. In contrast, MMSE
scores of 23 or higher showed increasing sensitivity, meaning that noncompetent persons with
MMSE scores above this value will likely not be mistakenly labeled as competent. Finally,
scores between 20 and 22 showed a gray zone of performance where the likelihood of being
competent or not was intermediate. Of particular value to these findings is that the MMSE
scores were close to t he scores used as standard cut points for staging the severity of
Alzheimer's disease.
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In summary, these results show that persons with very mild to moderate Alzheimer's disease
may well retain sufficient capacity to make a decision whether to take a risky treatment for
their disease, and this capacity is strongly associated with the preservation of insight into their
symptoms, diagnosis and, perhaps as well, prognosis.
The Capacity to Consent to Research
Decisions about research enrollment are ethically challenging. Unlike treatment, an activity
that aims to maximize a patient's good, research is an activity designed to create generalizable
knowledge. Consequently, research exposes participants to some procedures whose risks and
burdens are not justified by the potential to benefit each participant's health and well-being,
but instead by the value, or importance, of the know ledge that the study is designed to produce.
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Previous studies of Alzheimer's disease patients' capacity to consent to research have
examined the capacity to consent to a late-phase clinical trial [25]. Our group was especially
interested in studying a more ethically challenging situation: Alzheimer's disease patients'
capacity to consent to research that involved more than minimal risks. In particular, we were
interested in studying the capacity to consent to participate in an early-phase study designed
to test the safety of an intervention [26]. Such early-phase research is of particular scientific
value to inaugurate clinical testing of an intervention, but it also presents considerable ethical
challenges as the point of the study is to assess risks.
Measuring the Capacity to Consent to Research-We used the MacArthur
Competency Assessment Tool for Clinical Research (MacCA T-CR to assess the 4 decisionmaking abilities [27] among 3 groups: patients with probable Alzheimer's disease (n = 15),
their caregivers who had the role of making decisions for or with the patients (n = 15), and
elderly persons without cognitive impairment and not involved in a caregiving role (n = 15).
A trained interviewer read the subject a one-page description of an early-phase clinical trial
written at a 7th-grade reading level. To assure face and content validity, the description
contained the general requirements of an informed consent as described in the Common Rule
[28, § 46.116] for research informed consent, was based on published early-phase Alzheimer's
disease protocols [29] and a panel of Alzheimer's disease clinical investigators reviewed the
Neurosignals. Author ffianuscIipt; available in PMC 2009 July 29.
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description. The trial involved random assignment to daily intravenous injections of drug or
placebo in an inpatient facility for 1 week followed by weekly outpatient follow-up visits.
Standard language from other phase I Alzheimer's disease studies was used to describe the
risks and benefits.
The Capacity to Consent to Research in Persons with Alzheimer's Disease-On
all ability measures except the ability to make a choice, patients performed worse than controls
(understanding: z = 3.2, p = 0.001; appreciation: z = 2.8, p = 0.005; reasoning: z = 3.5, p =
0.0005) and caregivers (understanding: z = 3.8, p = 0.0002; appreciation: z = 3.0, p = 0.003;
reasoning: z = 3.6, p = 0.0003).
The value of comparison groups such as family caregivers and cognitively normal controls is
that they provide a criterion to compare patient performance. That is, the distribution of their
scores provides a 'psychometric criterion' that permits us to make conclusions about the
clinical significance of the distribution of patient scores. Using the controls' performance to
set a psychometric criterion, the proportions of patients with adequate understanding,
appreciation and reasoning were 6/15 (40%), 3/15 (20%) and 5/15 (33%), respectively. These
results show that nearly half of the patients scored within the range of cognitively normal
counterparts on the measure of understanding, but smaller proportions achieved this level of
performance on the measures of appreciation and reasoning.
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Proportions Judged Competent by Experienced Study Coordinator-A study
coordinator with 2 years of experience in Alzheimer's disease clinical trials reviewed each
audiotaped capacity interview. The coordinator judged all caregi vers and 9 of 15 (60%) patients
competent.
Relationships between Judgments of Competency and Cognitive FunctionMMSE scores of patients judged noncompetent by the study coordinator ranged between 12
and 27 (mean MMSE = 17.2 ± 5.7). In contrast, all competent patients had an MMSE score::::
19 (mean MMSE = 24.1 ± 3.1).
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These results are of considerable ethical importance. They show that some patients with
Alzheimer's disease retain sufficient capacity to consent to make their own decision whether
to enroll in an early-phase study to test the safety of a drug for persons with Alzheimer's disease.
Of particular value, they show that these kinds of patients are most likely persons with very
mild- to early moderate-stage Alzheimer's disease as measured by MMSE scores greater than
18. When set against the results of our study of the capacity to consent to treatment, they suggest
that while some degree of capacity impairment is a feature of even very mild-stage Alzheimer's
disease, these impairments achieve clinical significance in persons with moderate Alzheimer's
disease.
The Capacity to Make Everyday Decisions
Decisions about treatment and research are classic examples of decisions that invoke the need
to assess a patient's capacity. But there are other kinds of decisions for which capacity is just
as important. Our group has developed a conceptual model and instrument to measure the
ability of persons with Alzheimer's disease to make a very real-world decision: how to manage
their own functional problems [30,31].
We examined how a person who has a functional deficit, such as problems managing money,
understands and appreciates this problem, understands and appreciates the risks and benefits
of solutions to that problem and can reason through choices about how to solve this problem.
The instrument we have developed to measure this capacity is called the assessment of the
capacity for everyday decision making (ACED).
Neurosignais. Author manuscript; available in PMC 2009 July 29.
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ACED is valuable in at least 2 contexts: (1) at the time of planning discharge from a health
care setting such as a hospital or skilled nursing facility, and (2) in caring for persons with selfneglect, a syndrome characterized by an elderly person's inattention to health and hygiene,
typically as a result of their inability or unwillingness to accept assistance with their ADL.
In both contexts, persons who refuse assistance in performing their ADL are of particular
clinical and ethical concern. Clinicians need to assess if the person has sufficient capacity to
make this decision. This assessment not only has substantial implications on the course of
clinical interventions, but it may also initiate legal actions that may ultimately lead to partial
or complete guardianship. At the same time, however, persons who demonstrate sufficient
capacity to refuse assistance have the right to do so, even when such choices conflict with their
clinicians' recommendations.
Measuring Everyday Decision-Making Capacity-We focused on 2 of the 3
documented functional problems (managing medications, managing finances and preparing
meals). The order and heading for each ACED question are: understanding the problem (2
questions), appreciating the problem, understanding the options to solve the problem,
understanding the benefits of the options, understanding the harms of the options, appreciating
the benefits of the options (2 questions), appreciating the harms of the options, comparative
reasoning (2 questions), consequential reasoning (2 questions), expressing a choice, and the
logical consistency of that choice.
We studied 2 groups: 39 community-dwelling persons aged 65 or older who were being treated
for cognitive difficulties and were evenly divided into 3 stages of cognitive severity [very mild
(n = 13), mild (n = 13) and moderate (n = 13)] and a comparison group of 13 family members.
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The Capacity to Solve Everyday Functional Problems in Persons with Cognitive
Impairment-Although both groups were equally capable of articulating a choice, they
differed significantly in their abilities to understand, appreciate and reason. Caregiver
performance on all ACED items was skewed towards the higher ranges with all but one person
scoring within I point of the highest score.
In contrast, patient performance was distributed across the score ranges. Only 15 patients (38 %)
achieved an understanding score above the lowest score observed in the caregiver group. Only
6 patients (15%) scored in the highest category (7-8) of appreciation, whereas all caregivers
scored within the highest category. The majority of patients (29/39) scored between 1 and 4.
Contributing to the lower scores was notably poor performance on the appreciation item asking
patients whether they believed that they had functional problems. Specifically, 22/39 (56%)
demonstrated inadequate recognition (score = 0) of proxy-reported functional problems.
Performance on the ability to reason was similar to appreciation. Only 6 patients (15%) were
able to achieve scores of 9 or 10, the range of scores found in the caregiver group for this
ability. We did, however, observe total scores above 5 points in this ability for 30 patients
(77%), reflecting the relatively strong performance on the 2 comparative reasoning questions
and the logical consistency question where ::;3%of patients scored less than 1 on each item.
To validate the ACED, we compared the cognitively impaired patients' ACED scores to their
scores on the instrument we used to assess the capacity to make a treatment decision (MacCA TT). We observed a moderate to strong correlation between performance on the ACED and the
MacCAT -Tin each of the 4 decision-making abilities. Spearman correlation coefficients for
the abilities to appreciate and reason were 0.38 (p = 0.02) and 0.50 (p = 0.001), respectively.
There was a stronger association for the ability to understand and expressing a choice: 0.63 (p
< 0.001) and 0.71 (p < 0.001), respectively.
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These data show that we can measure a patient's ability to solve his or her everyday functional
problems using an instrument that took less than 15 min to administer and can be tailored to
fit each patient's specific functional deficits (for example, my husband has left the stove on
and bounced 2 checks). Further research is needed to assess the clinical significance of ACED
scores, especially those scores just below the range of performance seen in the cognitively
intact family members.

Summing Up and Looking Forward
Researchers have made substantial progress in applying the model of capacity assessment in
order to develop measures of the decision-making abilities. As a result, this research has
increased our understanding of the effects oflate-life cognitive impairment on a person's ability
to make decisions.
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Among persons with very mild- to moderate-stage Alzheimer's disease, there is relative
preservation of the abilities to choose and reason, compared to the abilities to understand and
appreciate. This finding is of substantial importance because it suggests that the standard
clinical approach of asking a person for his or her choice and then asking why the person made
that choice, that is, asking the person to reason, will likely miss that the person may have
substantial difficulties in understanding and appreciating information. Our studies of everyday
decision-making capacity using the ACED suggest that this is especially true in decisions about
managing everyday functional problems.
Progress has also been made in describing the clinical phenotype of the cognitively impaired
person who retains the capacity to consent. Our research shows that persons with preserved
awareness of their diagnosis, symptoms and prognosis are highly likely to retain capacity to
make decisions about their care. In addition, persons with very mild to mild dementia as defined
using standard MMSE cut points are more likely than those with moderate-stage disease to
retain the capacity to consent. However, there are other types of dementia that are distinct from
Alzheimer's disease (for example frontotemporal dementi as such as Pick's disease) in which
judgment, comportment and social behavior are affected more than memory early in the disease
course, and future studies should address the question of decision-making capacity in patients
affected by these other types of dementia.
Nonetheless, this progress in the Alzheimer's disease arena now opens the field to improve
patient care. We need to disseminate methods of capacity assessment to practitioners and
families. Preliminary work by Marson et al. [32] shows that instructing clinicians in the
standards for capacity assessment can improve agreement in their judgments of whether a
patient with Alzheimer's disease has adequate capacity.
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We also need to test methods to improve patient performance on measures of capacity, ideally
to improve performance to the degree that a person is judged capable of making a decision.
Our group will soon complete an investigator-initiated project grant (R-Ol) funded by the
National Institute of Aging that tests the benefit of a memory and organizational aid for research
consent capacity in persons wit h Alzheimer's disease. This randomized and controlled trial
tests whether a single-page summary sheet given to persons after reviewing a lengthy informed
consent form for an early-phase clinical trial can improve their decisional abilities and the odds
of being judged capable of giving one's own informed consent.
Of particular value is that this study examines the capacity to consent to an early-phase bridging
study. Such studies involve considerable uncertainties and thus risks to participants. It is the
kind of study for which investigators and institutional review boards would want to minimize
the chance that an investigator mistakenly judges a patient capable of consent when in fact the
patient cannot consent.
Neurosignals. Author manuscript; available in PMC 2009 July 29.
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Finally, these data are not only useful to guide ethical conduct of research and clinical care.
They are also useful to assess the effectiveness of interventions designed to improve or enhance
cognitive function. Specifically, measures of capacity could serve as endpoints in clinical trials
to test cognitive enhancement drugs.
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